Ribupatide trial reports weight loss and menstrual changes in women with PMOS

An investigational peptide targeting GLP-1 and GIP receptors produced greater weight loss than placebo in women with obesity and polyendocrine metabolic ovarian syndrome, according to Phase 2 findings presented October 1 at the European Association for the Study of Diabetes meeting in Milan. The ribupatide study also reported increased menstrual frequency, extending the research question beyond weight management to reproductive and metabolic health.

The presentation adds detail to an earlier announcement. Developer Hengrui disclosed topline findings on July 8; BioSpace reported the conference results on October 2. The distinction matters: these are additional findings from the same study, rather than an independent replication of its results.

### What the trial measured

The multicenter, randomized, double-blind trial enrolled 158 Chinese women aged 18–40 with PMOS and obesity. Participants received one of three ribupatide regimens or placebo for 32 weeks. The primary endpoint was percentage change in body weight.

Reported average weight reductions ranged from 10.0% to 20.2% across the active-treatment groups, compared with 2.6% for placebo. All three comparisons favored ribupatide statistically. The highest-treatment group therefore had a 17.6-percentage-point greater reduction than placebo; the 20.2% figure represents its total change from baseline.

Hengrui said its primary analysis followed a treatment-policy approach, retaining information after events such as premature treatment discontinuation or use of other weight-influencing medicines. That approach addresses a different question from an analysis restricted to uninterrupted treatment, and is relevant when comparing headline results across drug programs.

### Menstrual frequency and fertility are different outcomes

The conference abstract reported increased spontaneous menstrual frequency in all three ribupatide groups. It also examined regular cycles and ovulation, allowing a more qualified interpretation than a broad claim of restored reproductive function.

Regular menstrual cycles at week 32 were numerically more common with ribupatide, but the abstract did not report statistical significance for that comparison. Regular ovulation percentages were low and did not increase consistently across the treatment groups. These findings do not establish improved fertility, pregnancy rates or live births.

The study also cannot resolve whether reproductive changes reflect weight reduction, other drug effects, or a combination. Separating those possibilities would help determine which patients might benefit and which outcomes future trials should prioritize. A change in menstrual frequency should not automatically be interpreted as correction of every aspect of the syndrome.

### Safety and durability remain open questions

The abstract reported no serious adverse events and no adverse events leading to treatment discontinuation. Hengrui’s earlier release described most treatment-emergent events as mild and gastrointestinal. Those observations are encouraging within this study, but 158 participants followed for 32 weeks cannot establish the frequency of uncommon harms or safety over years of treatment.

The evidence also remains a conference report rather than a full peer-reviewed trial publication. Detailed reporting of missing data, individual adverse events and the statistical handling of multiple secondary outcomes would strengthen interpretation. The relatively narrow age range and single-country population limit generalization to other patients.

For healthspan research, the relevant next question is whether these changes translate into durable health benefits. This trial does not establish prevention of diabetes or cardiovascular disease, longer life, or sustained improvement after treatment ends. It supports further study of ribupatide in this population, with reproductive outcomes assessed separately from weight loss.